- Phase II or phase III window in various solid tumors (ie. sarcomas)
THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.
- Available as a 20 mg/mL solution
- Stable 24 hours at room temperature in D5W or NS
- Stable in D5W under refrigeration for 48 hours
- Protect from light
- Solutions Compatible: D5W preferred
- Y-site Compatible: D5W, NS or combinations
- NO COMPATIBILITY information available for other drugs
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
|IV Intermittent Infusion||
|IV Continuous Infusion||NO|
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- 50 mg/m2 daily x 5 days
20 mg/m2 daily x 5 days each week for 2 weeks
** Dosage may differ according to protocol
- Dosage adjustment may be required for hyperbilirubinemia or increase liver enzymes
- Patients with prior pelvic or abdominal radation have a greater risk of irinotecan-related toxicities; dose reduction may be necessary.
- Dizziness, nausea, vomiting
- Flushing, fever, sweating, chills, abdominal pain or cramping (cholinergic syndrome)
- Hypotension (6%)
- Not a vesicant, but may be irritating to peripheral veins. If extravasation occurs, click HERE for treatment guidelines.
Early Onset Diarrhea: (<24 hours) is cholinergic in nature. May rarely be severe, but is usually transient and can be accompanied by diaphoresis, flushing and cramping. May be managed with atropine (consult pre-printed orders or protocol for dose). Monitor blood pressure and heart rate during atropine. Late Onset Diarrhea: (>24 hours after last dose) prompt use of loperamide (Imodium) is recommended. Diarrhea may be prolonged and lead to dehydration and electrolyte imbalance. Consider admission for management. Consult protocol for details.
- Treatment for unusual side effects are available through the study chair identified on the front page of the protocol and/or pharmacy
- Irinotecan should not be administered to patients who are within 6 weeks of abdominal or pelvic irradiation
- Patients with Gilbert's syndrome may have increased risk of toxicity (re: difficulty eliminating active metabolite SN-38)
- Drug Interactions: carbamazepine, phenytoin, phenobarbital, chronic dexamethasone, ketoconazole and citalopram